Status:
COMPLETED
Investigating the Circulating Sphingolipidome Response to a Single High-intensity Interval Training Session
Lead Sponsor:
University of Basel
Collaborating Sponsors:
University of Lausanne
Conditions:
Physiological Response of Sphingolipids to a Single HIIT Session
Eligibility:
All Genders
20-29 years
Phase:
NA
Brief Summary
The purpose of this study is to examine the response of a comprehensive panel of circulating sphingolipids to a single high-intensity interval training (HIIT) session in healthy individuals in their t...
Detailed Description
Growing scientific evidence shows that specific sphingolipids, known as ceramides, predict cardiovascular risk beyond traditionally used biomarkers such as lipoproteins and triglycerides. Mechanistica...
Eligibility Criteria
Inclusion
- Female or male sex,
- Aged between 20 and 29 years old,
- Body Mass Index (BMI) between 18.5 and 24.9 kg/m2,
- Meeting the World Health Organization (WHO) guidelines on physical activity, i.e. at least 150-300 minutes of moderate-intensity aerobic physical activity per week as well as muscle-strengthening activities on 2 or more days per week,
- Clearance for physical activity according to the 2022 Physical Activity Readiness Questionnaire (PAR-Q+),
- Regular menstrual cycle,
- Informed consent as documented by signature.
Exclusion
- Females with known pregnancy or breastfeeding,
- Females with known polycystic ovary syndrome (PCOS),
- Current exercise-limiting conditions of the lower limbs (e.g. tendinopathy, fractures or other musculoskeletal pathologies),
- Known acute or chronic diseases: e.g. any active infectious diseases, any past or current malignant tumours, any lung diseases (e.g. bronchial asthma), any cardiometabolic diseases (e.g. arterial hypertension, diabetes, dyslipidaemia), any gastrointestinal diseases (e.g. coeliac disease, Crohn's disease, ulcerative colitis), any psychological disorders (e.g. depression, if medically diagnosed, anorexia, bulimia), any endocrinological diseases (e.g. all types of diabetes mellitus, hyper- or hypothyroidism), any nephrological diseases, any neurological disorders,
- Current or past smoking, current or past psychoactive drug use (alcohol excluded here, see below),
- Excessive alcohol consumption in the past two weeks, defined as either binge drinking (consuming five or more drinks during a single occasion) or heavy drinking (consuming 15 or more drinks per week),
- Any current or regular medication use, including any kind of hormonal contraception,
- Diet: vegetarian, vegan, lactose-free and gluten-free, FODMAP-free (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols),
- Inability to follow the procedures of the study, e.g. due to linguistic or cognitive problems,
- Concomitant involvement in another trial or participation in another trial in the last 4 weeks.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 4 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05390866
Start Date
September 1 2022
End Date
January 4 2023
Last Update
May 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel
Basel, Canton of Basel-City, Switzerland, 4052